ALDX News and Press, Aldeyra Therapeutics Inc. From 01/28/24

2024-01-28 02:56:00 ET Summary Aldeyra Therapeutics is a biotech company focused on developing treatments for immune-mediated inflammatory diseases, with its leading drug candidate being Reproxalap for dry eye and allergic conjunctivitis. The company has an option agreement with A...

Based on positive biomarker results observed in adult cohort of Phase 2 clinical trial of ADX-629 in Sjögren-Larsson Syndrome, proposed expansion to include pediatric patients expected to be submitted to the US Food and Drug Administration (FDA) in the first half of 2024 Phase 2 clin...

Disco Corporation ADR (DSCSY) is expected to report for Q2 2024 Sonic Foundry Inc. (SOFO) is expected to report for quarter end 2023-09-30 Sono Group N.V. (SEVCQ) is expected to report for quarter end 2023-09-30 Minim Inc (MINM) is expected to report for Q3 2023 Enel Spa ADR (ENLA...

2023-12-21 17:12:11 ET More on AbbVie, Aldeyra Therapeutics AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time AbbVie: $10 Billion Cancer Deal To Boost Growth Aldeyra stock jumps...

Enel Spa ADR (ENLAY) is expected to report for Q3 2023 LEG Immobilien SE Registered Shares (LEGIF) is expected to report for Q3 2023 G. Willi-Food International Ltd. (WILC) is expected to report for Q3 2023 Worthington Steel Inc. (WS) is expected to report $0.15 for Q2 2024 Sonic ...

2023-12-20 08:36:29 ET Losers: Bluebird bio BLUE -52% on pricing of $125 million stock offering . Jin Medical International Ltd ( ZJYL ) -14% . Argen X SE ( ARGX ) -25% reports topline results from address study of Efgartigimod SC in Pemphigus . ...

2023-12-19 11:40:50 ET More on Aldeyra Therapeutics Why I Am Selling Aldeyra Therapeutics: A Sour AbbVie Deal And A Lack Of Transparency Aldeyra:Upcoming PDUFA, Strong NDA, Long Pipeline, Decent Cash FDA says more data needed to approve Aldeyra dry eye drug (update) ...

Statistically significant improvement from baseline observed in investigator-assessed Eczema Area and Severity Index (EASI, p=0.0006) and Investigator Global Assessment (IGA, p<0.0001) EASI 75% improvement (EASI-75) threshold observed in three patients (38%), and affected body surface area...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET) to provide top-line results from a Phase 2 clinical trial of ADX‑629 in patients with atopic dermatitis. The dial-in numbers...

IMV Inc. (IMVIQ) is expected to report for Q3 2023 Orbit International Corp. (ORBT) is expected to report for quarter end 2023-09-30 PLx Pharma Winddown Corp. (PLXPQ) is expected to report for quarter end 2023-09-30 Advantage Energy Ltd (AAVVF) is expected to report for Q1 2024 We...